NCT02299089 · OUTCOME

Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Cmax.

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) · Source last updated 2017-12-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: ng/mL
Interval / dispersion: Standard Deviation
Time frame: (Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)

What was measured

Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84 ; Cmax (ng/mL). Cmax (ng/mL): Maximum observed plasma concentration over CAM2029 20 mg q4w and CAM2029 10 mg q2w dosing intervals (ng/mL)

Analysis population: Pharmacokinetic population, two patients excluded from the CAM2029 20mg Acromegaly due to incorrect dose.

Groups in this outcome

CAM2029 10 mg q2w (Acromegaly)

CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot

CAM2029 20 mg q4w (Acromegaly)

CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot

CAM2029 10 mg q2w (NET)

CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot

CAM2029 20 mg q4w (NET)

CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
CAM2029 10 mg q2w (Acromegaly)	3
CAM2029 20 mg q4w (Acromegaly)	2
CAM2029 10 mg q2w (NET)	1
CAM2029 20 mg q4w (NET)	4

Reported measurements

Cmax (ng/mL) Day 0

Analysis denominator · Participants

Group	Source count
CAM2029 10 mg q2w (Acromegaly)	3
CAM2029 20 mg q4w (Acromegaly)	2
CAM2029 10 mg q2w (NET)	1
CAM2029 20 mg q4w (NET)	3

Values in ng/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
CAM2029 10 mg q2w (Acromegaly)	10.4	6.62	Not reported	Not reported	Not reported
CAM2029 20 mg q4w (Acromegaly)	13.4	4.31	Not reported	Not reported	Not reported
CAM2029 10 mg q2w (NET)	6.33	NA	Not reported	Not reported	Single participant analyzed
CAM2029 20 mg q4w (NET)	16.3	8.67	Not reported	Not reported	Not reported

Cmax (ng/mL) Day 56

Analysis denominator · Participants

Group	Source count
CAM2029 10 mg q2w (Acromegaly)	2
CAM2029 20 mg q4w (Acromegaly)	2
CAM2029 10 mg q2w (NET)	1
CAM2029 20 mg q4w (NET)	4

Values in ng/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
CAM2029 10 mg q2w (Acromegaly)	10.6	10.2	Not reported	Not reported	Not reported
CAM2029 20 mg q4w (Acromegaly)	11.3	2.58	Not reported	Not reported	Not reported
CAM2029 10 mg q2w (NET)	5.61	NA	Not reported	Not reported	Single participant analyzed
CAM2029 20 mg q4w (NET)	15.7	4.05	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
6.62
value
10.4
group Id
OG001
spread
4.31
value
13.4
comment
Single participant analyzed
group Id
OG002
spread
NA
value
6.33
group Id
OG003
spread
8.67
value
16.3
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
3
units
Participants
title
Cmax (ng/mL) Day 0
categories
measurements
group Id
OG000
spread
10.2
value
10.6
group Id
OG001
spread
2.58
value
11.3
comment
Single participant analyzed
group Id
OG002
spread
NA
value
5.61
group Id
OG003
spread
4.05
value
15.7
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
4
units
Participants
title
Cmax (ng/mL) Day 56

denoms

counts
group Id
OG000
value
3
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
4
units
Participants

description

dispersion Type

Standard Deviation

groups

description
CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
id
OG000
title
CAM2029 10 mg q2w (Acromegaly)
description
CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
id
OG001
title
CAM2029 20 mg q4w (Acromegaly)
description
CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
id
OG002
title
CAM2029 10 mg q2w (NET)
description
CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
id
OG003
title
CAM2029 20 mg q4w (NET)

param Type

MEAN

population Description

Pharmacokinetic population, two patients excluded from the CAM2029 20mg Acromegaly due to incorrect dose.

reporting Status

POSTED

time Frame

(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)

title

Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Cmax.

type

PRIMARY

unit Of Measure

ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice